公开(公告)号：US20180111932A1

公开(公告)日：2018-04-26

申请号：US15788248

申请日：2017-10-19

Applicant: NOVARTIS AG

Inventor： Guillaume BARBE ,  Gregory Raymond BEBERNITZ ,  Sicong GENG ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Lv LIAO ,  Fupeng MA ,  Ruowei MO ,  David Thomas PARKER ,  Yunshan PENG ,  Stefan PEUKERT ,  Ken YAMADA ,  Kayo YASOSHIMA

IPC: C07D471/04 ,  A61K31/4375 ,  A61K45/06 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  C07F9/6561 ,  A61K31/675

CPC classification number: C07D471/04 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  A61P9/06 ,  C07B2200/13 ,  C07F9/6561

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20250092036A1

公开(公告)日：2025-03-20

申请号：US18800559

申请日：2024-08-12

Applicant: Novartis AG

Inventor： Erich W. BAUM ,  Thomas A. DINEEN, JR. ,  Jonathan Edward HEMPEL ,  Matthew James HESSE ,  Robert KOENIG ,  Matthew James LAMARCHE ,  Jay Francis LARROW ,  Ruowei MO ,  Henrik MOEBITZ ,  Rukundo NTAGANDA ,  Keith Bruce PFISTER ,  Martin SENDZIK ,  Colin Keith SKEPPER ,  Joseph WZOREK, JR. ,  Frédéric ZECRI

IPC: C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61P35/00 ,  C07D401/06 ,  C07D405/14 ,  C07D491/052

Abstract: The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.

公开(公告)号：US20210284635A1

公开(公告)日：2021-09-16

申请号：US17071311

申请日：2020-10-15

Applicant: NOVARTIS AG

Inventor： Guillaume BARBE ,  Gregory Raymond BEBERNITZ ,  Sicong GENG ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Lv LIAO ,  Fupeng MA ,  Ruowei MO ,  David Thomas PARKER ,  Yunshan PENG ,  Stefan PEUKERT ,  Nichola Smith ,  Ken YAMADA ,  Kayo YASOSHIMA

IPC: C07D471/04 ,  A61P9/06 ,  A61K31/4375 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/675 ,  A61K45/06 ,  C07F9/6561

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20190263803A1

公开(公告)日：2019-08-29

申请号：US16290313

申请日：2019-03-01

Applicant: NOVARTIS AG

Inventor： Guillaume BARBE ,  Gregory Raymond BEBERNITZ ,  Sicong GENG ,  Hatice Belgin GULGEZE EFTHYMIOU ,  Lv LIAO ,  Fupeng MA ,  Ruowei MO ,  David Thomas PARKER ,  Yunshan PENG ,  Stefan PEUKERT ,  Ken YAMADA ,  Kayo YASOSHIMA

IPC: C07D471/04 ,  A61P9/06 ,  A61K31/675 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4375 ,  C07F9/6561 ,  A61K45/06 ,  A61K31/541

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; Wherein R1, R3-R6, X2 and X3 are as defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.